According to a recent news feature from Yahoo Finance, industry experts are predicting that there will be a roughly 4 percent increase in the world testosterone replacement therapy market over the next handful of years. While this may seem like a good thing for the testosterone hormone industry, it is actually a relatively modest rise as compared to the huge increases we have seen in the past decade or so.
Prior to a huge marketing effort from the drug companies that manufacture testosterone replacement therapy (TRT) hormone, the drug was only used to treat a very rare condition known as hypogonadism. Hypogonadism is a rare condition that results in a patient not developing enough testosterone hormone for proper development or proper function. These numbers are extremely low. Continue reading